Object Assessment of Improvement in Non-Specific Symptoms After Parathyroidectomy for Primary Hyperparathyroidism
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 45 people enrolled
- Started
- 19 Jul 2022
- Ended
- 29 Jun 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Activity Tracker (Fitbit)
- HbA1C
- The PROMPT Questionnaire
- Record updated
- 6 August 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Study group: Consecutive patients older than 18 years old who will undergo PTX for PHPT. The indications and need for surgery will be independent from the research team
- Control group: Consecutive patients older than 18 years old who will undergo thyroidectomy for multinodular goiter (MNG). The indications and need for surgery will be independent from the research team
Who cannot take part
- Sleep apnea and other sleep disturbances undergoing concurrent treatment
- Established diagnosis of thyroid cancer or Graves' disease
- Musculoskeletal or neurologic disorders that affect the patient's activity level
- Cardiac arrhythmias that would interfere with the wearable electronic device measurement
- Patients who are included but have evidence of recurrent or persistent PHPT based on six-month laboratory workup will be excluded from the final analysis (<5% expected)4
- Patients with recurrent or persistent PHPT will not be included
Where in United States
- The Cleveland Clinic FoundationCleveland, United States
About the trial
What the trial wants to find out
Wearable electronic devices are becoming more prevalent in daily life, as they offer real time information on physiological parameters such as heart rate, activity level, oxygenation, and sleep patterns for their users. These wearable electronic devices are easy to install and offer no major risk or discomfort to the user. Implementation of these technologies into medicine has exponentially grown in the past decade with supporting evidence for their use in cardiovascular disease and sleep medicine. The investigators believe that these devices will be able to capture the changes associated with improvement in non-specific symptoms that have not been previously demonstrated.
The 2 groups in the trial
- 40 patients with primary hyperparathyroidism
patients undergoing parathyroidectomy for primary hyperparathyroidism
Treatment: Activity Tracker (Fitbit), HbA1C, and The PROMPT Questionnaire
- 40 patients with multinodular goiters
patients undergoing thyroidectomy for multinodular goiter
Treatment: Activity Tracker (Fitbit), HbA1C, and The PROMPT Questionnaire
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 August 2024